Maurizio S Riga

Dr. Maurizio S Riga

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in Neuropharmacology
Verified
Journal Article
Open access
MRMaurizio S Riga
Maurizio S Riga
CSConnie Sánchez
Connie Sánchez
PCPau Celada
Pau Celada
FAFrancesc Artigas
Francesc Artigas
The antidepressant vortioxetine is a 5-HT3-R, 5-HT7-R and 5-HT1D-R antagonist, 5-HT1B-R partial agonist, 5-HT1A-R agonist, and serotonin (5-HT) transporter (SERT) inhibitor. Vortioxetine occupies all targets at high therapeutic doses and only SERT and 5-HT3-R at low doses. Vortioxetine increases extracellular monoamine concentrations in rat forebrain more than selective serotonin reuptake inhibitors (SSRI) and shows pro-cognitive activity in preclinical models. Given its high affinity for 5-HT3-R (Ki = 3.7 nM), selectively expressed in GABA interneurons, we hypothesized that vortioxetine may disinhibit glutamatergic and monoaminergic neurotransmission following 5-HT3-R blockade. Here we assessed vortioxetine effect on pyramidal neuron activity and extracellular 5-HT concentration using in vivo extracellular recordings of rat medial prefrontal cortex (mPFC) pyramidal neurons and microdialysis in mPFC and ventral hippocampus (vHPC). Vortioxetine, but not escitalopram, increased pyramidal neuron discharge in mPFC. This effect was prevented by SR57227A (5-HT3-R agonist) and was mimicked by ondansetron (5-HT3-R antagonist) and by escitalopram/ondansetron combinations. In microdialysis experiments, ondansetron augmented the 5-HT-enhancing effect of escitalopram in mPFC and vHPC. Local ondansetron in vHPC augmented escitalopram effect, indicating the participation of intrinsic mechanisms. Since 5-HT neurons express GABAB receptors, we examined their putative involvement in controlling 5-HT release after 5-HT3-R blockade. Co-perfusion of baclofen (but not muscimol) reversed the increased 5-HT levels produced by vortioxetine and escitalopram/ondansetron combinations in vHPC. The present results suggest that vortioxetine increases glutamatergic and serotonergic neurotransmission in rat forebrain by blocking 5-HT3 receptors in GABA interneurons.

20 March 2014 in International Journal of Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
MRMaurizio S Riga
Maurizio S Riga
GSGuadalupe Soria
Guadalupe Soria
RTRaúl Tudela
Raúl Tudela
FAFrancesc Artigas
Francesc Artigas
PCPau Celada
Pau Celada
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a natural hallucinogen component of Ayahuasca, an Amazonian beverage traditionally used for ritual, re


19 October 2011 in Neuropsychopharmacology
Verified
Journal Article
Closed access
LKLucila Kargieman
Lucila Kargieman
MRMaurizio S Riga
Maurizio S Riga
FAFrancesc Artigas
Francesc Artigas
PCPau Celada
Pau Celada

4 November 2016 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
FAFrancesc Artigas
Francesc Artigas
ESEsther Schenker
Esther Schenker
PCPau Celada
Pau Celada
MSMichael Spedding
Michael Spedding
LLLaia Lladó-Pelfort
Laia Lladó-Pelfort
ASAdam J. Schwarz
Adam J. Schwarz

1 November 2013 in International Journal of Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
PCPau Celada
Pau Celada
LLLaia Lladó-Pelfort
Laia Lladó-Pelfort
NSN. Santana
N. Santana
LKL. Kargieman
L. Kargieman
ETEva Troyano-Rodriguez
Eva Troyano-Rodriguez
FAFrancesc Artigas
Francesc Artigas
Non-competitive NMDA receptor antagonists are widely used as pharmacological models of schizophrenia due to their ability to evoke the symptoms of the illness. Likewise, serotonergic hallucinogens, acting on 5-HT2A receptors, induce perceptual and behavioural alterations possibly related to psychotic symptoms. The neurobiological basis of these alterations is not fully elucidated. Data obtained in recent years revealed that the NMDA receptor antagonist phencyclidine (PCP) and the serotonergic hallucinogen 1-(2,5-dimethoxy-4-iodophenyl-2-aminopropane; DOI) produce a series of common actions in rodent prefrontal cortex (PFC) that may underlie psychotomimetic effects. Hence, both agents markedly disrupt PFC function by altering pyramidal neuron discharge (with an overall increase) and reducing the power of low frequency cortical oscillations (LFCO; < 4 Hz). In parallel, PCP increased c-fos expression in excitatory neurons of various cortical areas, the thalamus and other subcortical structures, such as the amygdala. Electrophysiological studies revealed that PCP altered similarly the function of the centromedial and mediodorsal nuclei of the thalamus, reciprocally connected with PFC, suggesting that its psychotomimetic properties are mediated by an alteration of thalamocortical activity (the effect of DOI was not examined in the thalamus). Interestingly, the observed effects were prevented or reversed by the antipsychotic drugs clozapine and haloperidol, supporting that the disruption of PFC activity is intimately related to the psychotomimetic activity of these agents. Overall, the present experimental model can be successfully used to elucidate the neurobiological basis of schizophrenia symptoms and to examine the potential antipsychotic activity of new drugs in development.